within Pharmacolibrary.Drugs.S_SensoryOrgans.S01F_MydriaticsAndCycloplegics.S01FA02_Scopolamine;

model Scopolamine_1
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C_enteral(
    weight = 70,
    F = 0.06,
    Cl = 1.716666666666667e-05,
    adminDuration = 600,
    adminMass = 0.4 / 1000000,
    adminCount = 1,
    Vd = 0.0070999999999999995,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.0010833333333333333,
    Tlag = 600,
    Vdp = 0.0062,
    k12 = 1.7333333333333336e-05,
    k21 = 1.7333333333333336e-05);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Scopolamine_1</td></tr><tr><td>ATC code:</td><td>S01FA02_1</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>0.4</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>7.1</td><td>L</td></tr>
    <tr><td>clearance:</td><td>1.03</td><td>L/min</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Scopolamine, also known as hyoscine, is a tropane alkaloid anticholinergic drug used primarily for the prevention of motion sickness, postoperative nausea and vomiting, and as a mydriatic and cycloplegic agent in ophthalmology. It is available in various formulations including oral, transdermal, and parenteral administration. Scopolamine is still in clinical use today, mainly for its antiemetic properties and ophthalmological purposes.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adults after oral administration.</p><h4>References</h4><ol><li><p>Tytgat, GN (2007). Hyoscine butylbromide: a review of its use in the treatment of abdominal cramping and pain. <i>Drugs</i> 67(9) 1343–1357. DOI:<a href=\"https://doi.org/10.2165/00003495-200767090-00007\">10.2165/00003495-200767090-00007</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/17547475/\">https://pubmed.ncbi.nlm.nih.gov/17547475</a></p></li><li><p>Guay, DR (2003). Clinical pharmacokinetics of drugs used to treat urge incontinence. <i>Clinical pharmacokinetics</i> 42(14) 1243–1285. DOI:<a href=\"https://doi.org/10.2165/00003088-200342140-00004\">10.2165/00003088-200342140-00004</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/14606931/\">https://pubmed.ncbi.nlm.nih.gov/14606931</a></p></li><li><p>Rompicherla, SKL, et al., &amp; Rao, CM (2021). Pharmacokinetic and pharmacodynamic evaluation of nasal liposome and nanoparticle based rivastigmine formulations in acute and chronic models of Alzheimer&#x27;s disease. <i>Naunyn-Schmiedeberg&#x27;s archives of pharmacology</i> 394(8) 1737–1755. DOI:<a href=\"https://doi.org/10.1007/s00210-021-02096-0\">10.1007/s00210-021-02096-0</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/34086100/\">https://pubmed.ncbi.nlm.nih.gov/34086100</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.S.S01FA02_1 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Scopolamine_1;
